Superworth

Anika Therapeutics price to free cash flow ANIK

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Nov 2, 2026
462×
10-year median
32.0×
Against its 10-year history
98th
percentile: 0 is its lowest day, 100 its highest
10-year range
10.7× to 499×
Peer median
12.2×

Anika Therapeutics' price to free cash flow is 462× as of Nov 2, 2026.

That is above its ten-year median of 32.0×, higher than on 98% of days in the last ten years.

Over that time it ranged from 10.7× in Mar 2020 to 499× in Oct 2026.

The median for 10 medical instruments and supplies stocks of a similar size is 12.2×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far462×42.5×499×
2025213×213×222×
2024215×215×335×
2023165×165×202×
2022187×95.7×242×
2021253×22.3×318×
202029.2×10.7×29.2×
201924.1×13.8×32.3×
201818.2×17.2×31.3×
201724.9×24.1×69.1×
201653.3×15.0×57.2×
201515.6×13.2×19.9×
201417.6×14.8×27.1×
201323.6×11.5×25.0×
201211.7×11.7×36.7×

Against its peers

Companies in Medical - Instruments & Supplies nearest Anika Therapeutics' size, closest first, today.

CompanyPrice to free cash flow
ANIKAnika Therapeutics462×
INFUInfuSystem12.0×
UTMDUtah Medical Products19.6×
EMBCEmbecta2.1×
PDEXPro DEX17.3×
TCMDTactile Systems Technology19.3×
KEQUKewaunee Scientific8.9×
MOVMovado10.0×
IRMDIradimed38.9×
IARTIntegra Lifesciences12.3×
BVSBioventus11.7×
Peer median12.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Anika Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.